picankibart

Picankibart is a monoclonal antibody developed by Innovent Biologics that specifically targets the interleukin-23 p19 (IL-23p19) subunit, thereby inhibiting IL-23 from binding to its cell surface receptor and blocking downstream signaling. This mechanism disrupts the IL-23 pathway, which plays a key role in inflammatory and autoimmune diseases. Picankibart has demonstrated high efficacy in clinical trials for moderate to severe plaque psoriasis, with over 80% of subjects achieving PASI 90 after 16 weeks of treatment and sustained benefits through one year. It also offers a long maintenance dosing interval (once every 12 weeks), potentially improving patient convenience. In addition to psoriasis, picankibart is being investigated for ulcerative colitis and other autoimmune conditions[1][2][3][4][5][6][7].

Brand names

Picankibart

Other names

anti-interleukin 23p19 subunit antibody injectionanti-interleukin23p19 subunit antibody injectionanti-interleukin-23p19 subunit antibody injection